uniQure Q2 net loss $56.3M; restructures to cut 65% of workforce, burn by $75M/yr

uniQure N.V.

2024-Q2 EPS reported -$2.51 revenue$19,611,000

Net loss $56.3M ($1.16 EPS) vs $68.5M ($1.44 EPS) in Q2 2023; revenue $11.1M up from $2.4M.
Restructuring: 65% headcount reduction (~300 roles), sale of Lexington facility, $75M annual cash burn cut including $50M debt retirement.
Cash $524M as of June 30, expected to fund operations through end 2027.
FDA granted RMAT designation for AMT-130 in Huntington's; interim data showed dose-dependent slowing of disease progression and reduced NfL.
Patient screening started for three new Phase I/II trials (AMT-260 mTLE, AMT-191 Fabry, AMT-162 SOD1 ALS); enrollment expected Q3 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.